Cargando…

Real-life cost-effectiveness of benralizumab in patients with severe asthma

BACKGROUND: Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems. The aim of this study was to evaluate clinical outcomes and healthcare expenditure after incorporating benralizumab into the standard trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Padilla-Galo, A., García-Ruiz, A. J., Levy Abitbol, R. Ch., Olveira, C., Rivas-Ruiz, F., García-Agua Soler, N., Pérez Morales, M., Valencia Azcona, B., Tortajada-Goitia, B., Moya-Carmona, I., Levy-Naon, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155800/ https://www.ncbi.nlm.nih.gov/pubmed/34044819 http://dx.doi.org/10.1186/s12931-021-01758-0

Ejemplares similares

Real-life experience with benralizumab during 6 months
por: Padilla-Galo, A., et al.
Publicado: (2020)

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study
por: Padilla-Galo, Alicia, et al.
Publicado: (2023)

Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients
por: Padilla-Galo, A., et al.
Publicado: (2018)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
por: Menzies-Gow, Andrew, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
por: Wang, B, et al.
Publicado: (2017)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
por: Just, Jocelyne, et al.
Publicado: (2020)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
por: Gómez-Bastero Fernández, Ana, et al.
Publicado: (2022)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Benralizumab: a unique IL-5 inhibitor for severe asthma
por: Tan, Laren D, et al.
Publicado: (2016)

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
por: Yan, Li, et al.
Publicado: (2019)

Postbronchodilator lung function improvements with benralizumab for patients with severe asthma
por: Mathur, Sameer K., et al.
Publicado: (2020)

Real world effectiveness of benralizumab on respiratory function and asthma control
por: Menzella, Francesco, et al.
Publicado: (2021)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
por: Martínez-Rivera, Carlos, et al.
Publicado: (2021)

Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma
por: Cañas, José A., et al.
Publicado: (2021)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
por: Pelaia, Corrado, et al.
Publicado: (2018)

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
por: Bleecker, Eugene R., et al.
Publicado: (2018)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019)

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
por: Chia, Yen Lin, et al.
Publicado: (2019)

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma
por: FitzGerald, J Mark, et al.
Publicado: (2019)

Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
por: Cheng, Shih-Lung
Publicado: (2021)

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
por: Chan, Rory, et al.
Publicado: (2023)

Evaluation of a protocol to detect malnutrition and provide nutritional care for cancer patients undergoing chemotherapy
por: Álvaro Sanz, Elena, et al.
Publicado: (2020)

Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab
por: Ricciardi, Luisa, et al.
Publicado: (2022)

Impact of a nutrition consultation on the rate of high output stoma-related readmission: an ambispective cohort study
por: Santamaría, Manuela Moreno, et al.
Publicado: (2021)

Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma
por: Ferguson, Gary T, et al.
Publicado: (2018)

Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis
por: Liu, Wanshu, et al.
Publicado: (2019)

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma
por: Yamada, Hideyasu, et al.
Publicado: (2021)

Medium-term repeatability for airwave oscillometry in patients with severe asthma taking benralizumab
por: Chan, Rory, et al.
Publicado: (2023)

Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma
por: Goyack, Laura, et al.
Publicado: (2023)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma
por: Jackson, David J., et al.
Publicado: (2019)

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
por: Menzies-Gow, Andrew, et al.
Publicado: (2022)

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
por: Tsurumaki, Hiroaki, et al.
Publicado: (2019)

Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab
por: Minami, Daisuke, et al.
Publicado: (2018)

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
por: Caminati, Marco, et al.
Publicado: (2019)

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
por: Numata, Takanori, et al.
Publicado: (2020)

Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use
por: Nolasco, Santi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gr3vt1aa5bm7kb9d61u83rp3cn